We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease
Weight loss and fatty liver changes after treatment with tirzepatide versus weight loss surgery
AI simplified
Abstract
resulted in a 15.5% weight reduction in obese rats.
- Semaglutide treatment led to a 10.7% weight reduction in rats fed a high-fat diet.
- treatment resulted in weight reductions of 5.0%, 14.9%, and 17.7% at concentrations of 10, 50, and 100 nmol/kg, respectively.
- Metabolic analyte levels decreased in rats treated with semaglutide and tirzepatide compared to the sham group.
- Adipose tissue weight and liver fat droplets were reduced in the intervention groups.
- Tirzepatide, especially at higher doses, showed greater improvements in metabolic parameters compared to bariatric surgery and semaglutide.
AI simplified
Key numbers
17.7%
Weight Reduction with
Weight loss in rats treated with at 100 nmol/kg.
15.5%
Weight Reduction with
Weight loss in rats following after 6 weeks.
10.7%
Weight Reduction with
Weight loss in rats treated with after 6 weeks.